Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: The LOTUS randomized clinical trial

JAMA

Volumn 305, Issue 19, 2011, Pages 1969-1977

  Galmiche, Jean Paul ^a   Hatlebakk, Jan ^b   Attwood, Stephen ^c   Ell, Christian ^d   Fiocca, Roberto ^e   Eklund, Stefan ^f   Långström, Göran ^f   Lind, Tore ^f   Lundell, Lars ^g  

^a UNIVERSITÉ DE NANTES   (France)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c NORTH TYNESIDE GENERAL HOSPITAL   (United Kingdom)

^d DR HORST SCHMIDT KLINIKEN   (Germany)

^e UNIVERSITY OF GENOA   (Italy)

^f ASTRAZENECA R AND D   (Sweden)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN; ESOMEPRAZOLE; GASTRIN;

ADULT; AGED; ANTIREFLUX OPERATION; ARTICLE; BLOATING; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE CONTROL; DISEASE SEVERITY; DRUG DOSE INCREASE; DYSPHAGIA; EUROPE; EXPLORATORY RESEARCH; FEMALE; FLATULENCE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; LAPAROSCOPIC SURGERY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; STANDARDIZATION; STOMACH ACID; TREATMENT FAILURE; TREATMENT RESPONSE;

EID: 79956146775     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.626     Document Type: Article

References (30)

1. Kulig M, Leodolter A, Vieth M, et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease - an analysis based on the ProGERD initiative. Aliment Pharmacol Ther. 2003;18(8):767-776. (Pubitemid 37323641)
2. Wahlqvist P, Reilly MC, Barkun A. Systematic review: the impact of gastro-oesophageal reflux disease on work productivity. Aliment Pharmacol Ther. 2006;24(2):259-272. (Pubitemid 43972894)
3. Camilleri M, Dubois D, Coulie B, et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol. 2005;3(6):543-552. (Pubitemid 40824747)
4. McQuaid KR, Laine L. Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials. Clin Gastroenterol Hepatol. 2005;3(6):553-563. (Pubitemid 40824748)
5. Gralnek IM, Dulai GS, Fennerty MB, Spiegel BMR. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: ameta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol. 2006;4(12):1452-1458. (Pubitemid 44895413)
6. Edwards SJ, Lind T, Lundell L. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs. Aliment Pharmacol Ther. 2006;24(5):743-750.
7. Peters MJ, Mukhtar A, Yunus RM, et al. Meta-analysis of randomized clinical trials comparing open and laparoscopic anti-reflux surgery. Am J Gastroenterol. 2009;104(6):1548-1561.
8. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA. 2001;285(18):2331-2338. (Pubitemid 32424101)
9. Lundell L, Miettinen P, Myrvold HE, et al; Nordic GERD Study Group. Comparison of outcomes 12 years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. Clin Gastroenterol Hepatol. 2009;7(12):1292-1298, quiz 1260.
10. Mahon D, Rhodes M, Decadt B, et al. Randomized clinical trial of laparoscopic Nissen fundoplication compared with proton-pump inhibitors for treatment of chronic gastro-oesophageal reflux. Br J Surg. 2005;92(6):695-699. (Pubitemid 40863187)
11. Anvari M, Allen C, Borm A. Laparoscopic Nissen fundoplication is a satisfactory alternative to long-term omeprazole therapy. Br J Surg. 1995;82(7):938-942.
12. Mehta S, Bennett J, Mahon D, Rhodes M. Prospective trial of laparoscopic Nissen fundoplication vs proton pump inhibitor therapy for gastroesophageal reflux disease: 7-year follow-up. J Gastrointest Surg. 2006;10(9):1312-1316.
13. Grant AM, Wileman SM, Ramsay CR, et al; REFLUX Trial Group. Minimal access surgery compared with medical management for chronic gastro-oesophageal reflux disease: UK collaborative randomised trial. BMJ. 2008;337:a2664.
14. Attwood SE, Lundell L, Ell C, et al; LOTUS Trial Group. Standardization of surgical technique in anti-reflux surgery: the LOTUS trial experience. World J Surg. 2008;32(6):995-998.
15. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 2002;97(3):575-583. (Pubitemid 34245883)
16. Lundell L, Attwood S, Ell C, et al; LOTUS Trial Collaborators. Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial. Gut. 2008;57(9):1207-1213.
17. Fiocca R, Mastracci L, Engström C, et al; LOTUS Trial Collaborators. Long-term outcome of microscopic esophagitis in chronic GERD patients treated with esomeprazole or laparoscopic antireflux surgery in the LOTUS trial. Am J Gastroenterol. 2010;105(5):1015-1023.
18. Hatlebakk JG, Zerbib F, Bonavina L, et al. Control of acid reflux 5 years after laparoscopic anti-reflux surgery (LARS) compared to long-term treatment with esomeprazole 20-40 mg daily (ESO) in the LOTUS study. Gut. 2010;59(suppl 3):A87.
19. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York, NY: Wiley; 1981.
20. Ell C, Lundell LR, Seiler CM, et al. Safety profile in GERD patients 5 years after laparoscopic antireflux surgery or long-term treatment with esomeprazole 20-40 mg daily in the LOTUS study. Gastroenterology. 2010;138(5)(suppl 1):S-654.
21. Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a 5-way cross-over study. Am J Gastroenterol. 2003;98(12):2616-2620.
22. Röhss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol. 2004;60(8):531-539. (Pubitemid 39517904)
23. Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther. 1998;12(12):1235-1240. (Pubitemid 28565964)
24. Luostarinen MES, Isolauri JO. Surgical experience improves the long-term results of Nissen fundoplication. Scand J Gastroenterol. 1999;34(2):117-120. (Pubitemid 29138858)
25. Oelschlager BK, Quiroga E, Parra JD, Cahill M, Polissar N, Pellegrini CA. Long-term outcomes after laparoscopic antireflux surgery. Am J Gastroenterol. 2008;103(2):280-287. (Pubitemid 351248718)
26. Moayyedi P, Cranney A. Hip fracture and proton pump inhibitor therapy: balancing the evidence for benefit and harm. Am J Gastroenterol. 2008;103(10):2428-2431.
27. Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010;138(3):896-904.
28. Lodato F, Azzaroli F, Turco L, et al. Adverse effects of proton pump inhibitors. Best Pract Res Clin Gastroenterol. 2010;24(2):193-201.
29. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947-2953. (Pubitemid 46021498)
30. Zaninotto G, Attwood SE. Surgical management of refractory gastro-oesophageal reflux. Br J Surg. 2010;97(2):139-140.